A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evalution the Safety, Tolerability of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old
Latest Information Update: 10 Apr 2024
At a glance
- Drugs Inactivated rotavirus vaccine Beijing Zhifei Lvzhu Biopharmaceutical (Primary)
- Indications Rotavirus infections
- Focus Adverse reactions
- Sponsors Beijing Zhifei Lvzhu Biopharmaceutical
Most Recent Events
- 10 Apr 2024 New trial record